Fifth Third Bancorp
ANIP icon

Fifth Third Bancorp’s ANI Pharmaceuticals ANIP Stock Holding History

Fifth Third Bancorp’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$708K Sell
8,548
-824
-9% -$66.1K ﹤0.01% 1899
2026
Q1 		$721K Buy
9,372
+9,318
+17,256% +$727K ﹤0.01% 1826
2025
Q4 		$4.26K Sell
54
-3
-5% -$260 ﹤0.01% 2333
2025
Q3 		$5.22K Buy
57
+32
+128% +$2.61K ﹤0.01% 2324
2025
Q2 		$1.63K Buy
25
+10
+67% +$651 ﹤0.01% 2373
2025
Q1 		$1K Buy
+15
New +$896 ﹤0.01% 2395
2024
Q4 		– Sell
-12
Closed -$716 – 2513
2024
Q3 		$716 Buy
+12
New +$732 ﹤0.01% 2480
2024
Q2 		– Sell
-2
Closed -$138 – 2451
2024
Q1 		$138 Buy
+2
New +$121 ﹤0.01% 2351
2022
Q2 		– Sell
-4
Closed – – 2639
2022
Q1 		$0 Sell
4
-78
-95% -$2.91K ﹤0.01% 2661
2021
Q4 		$4K Buy
82
+78
+1,950% +$3.35K ﹤0.01% 2375
2021
Q3 		$0 Sell
4
-96
-96% -$2.98K ﹤0.01% 2636
2021
Q2 		$4K Buy
+100
New +$3.4K ﹤0.01% 2227
2020
Q1 		– Sell
-5,832
Closed -$360K – 2114
2019
Q4 		$360K Buy
5,832
+1,020
+21% +$67.6K ﹤0.01% 753
2019
Q3 		$351K Sell
4,812
-133
-3% -$9.95K ﹤0.01% 744
2019
Q2 		$406K Sell
4,945
-1,550
-24% -$110K ﹤0.01% 686
2019
Q1 		$458K Sell
6,495
-807
-11% -$47.5K ﹤0.01% 628
2018
Q4 		$329K Sell
7,302
-2,648
-27% -$139K ﹤0.01% 724
2018
Q3 		$563K Buy
9,950
+172
+2% +$10.5K ﹤0.01% 659
2018
Q2 		$653K Sell
9,778
-454
-4% -$28.3K ﹤0.01% 616
2018
Q1 		$596K Buy
10,232
+1,559
+18% +$99K ﹤0.01% 620
2017
Q4 		$559K Sell
8,673
-574
-6% -$35.7K ﹤0.01% 661
2017
Q3 		$485K Sell
9,247
-233
-2% -$11.1K ﹤0.01% 679
2017
Q2 		$444K Sell
9,480
-1,370
-13% -$66.1K ﹤0.01% 719
2017
Q1 		$537K Buy
10,850
+2,424
+29% +$136K ﹤0.01% 684
2016
Q4 		$511K Sell
8,426
-648
-7% -$39.6K ﹤0.01% 714
2016
Q3 		$602K Buy
+9,074
New +$568K 0.01% 677

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fifth Third Bancorp's ANIP Position: Q2 2026 in Review

Fifth Third Bancorp reduced its ANI Pharmaceuticals (ANIP) stake by 8.8% in Q2 2026, selling an estimated $66.1K and leaving 8,548 shares worth $708K. The position accounts for ﹤0.01% of the portfolio, ranked #1899.

Fifth Third Bancorp first reported a position in ANIP in Q3 2016 and has held it in 26 quarters since. The position peaked at $721K in Q1 2026. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Fifth Third Bancorp held 8,548 shares of ANI Pharmaceuticals worth $708K as of Q2 2026.
  • Fifth Third Bancorp sold 824 ANI Pharmaceuticals shares in Q2 2026, an estimated $66.1K.
  • ANI Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #1899 holding.
  • Fifth Third Bancorp first reported a position in ANI Pharmaceuticals in Q3 2016 and has held it in 26 quarters since.
  • Fifth Third Bancorp's ANI Pharmaceuticals position peaked at $721K in Q1 2026.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.